Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Jeffrey Settleman, Sreenath V. Sharma et al.|Proceedings of the National Academy of Sciences|2007Cited by 358
Targeting constitutively active <scp>STAT3</scp> in chronic lymphocytic leukemia: A clinical trial of the <scp>STAT3</scp> inhibitor pyrimethamine with pharmacodynamic analysesJennifer R. Brown, David A. Frank, Sarah R. Walker et al.|American Journal of Hematology|2020Cited by 29
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJ. R. Brown, AS Freedman, Bradley T. Messmer et al.|Haematologica|2013Cited by 14
Multimodal platform for assessing drug distribution and response in clinical trialsBegoña Giménez, Nathalie Y.R. Agar, Sankha S. Basu et al.|Neuro-Oncology|2021Cited by 14
Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigationSeth A. Wander, Aditya Bardia, Douglas S. Micalizzi et al.|Cancer Research|2022Cited by 1